Darunavir Outcomes Study: Comparative Effectiveness of Virologic Suppression, Regimen Durability, and Discontinuation Reasons for Three-Class Experienced Patients at 48 Weeks

Several new antiretroviral (ARV) agents for treatment experienced HIV-infected patients have been approved since June 2006, including darunavir (DRV) and raltegravir (RAL). While efficacious in clinical trials, the effectiveness, durability, and tolerability of these new ARVs remains understudied in...

Full description

Saved in:
Bibliographic Details
Main Authors: Willig, James H., Aban, Inmaculada, Nevin, Christa R., Ye, Jiatao, Raper, James L., McKinnel, James A., DeLaitsch, Lori L., Mrus, Joseph M., De La Rosa, Guy R., Mugavero, Michael J., Saag, Michael S.
Format: Artigo
Language:Inglês
Published: Mary Ann Liebert, Inc. 2010
Subjects:
Outcomes Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3011996/
https://ncbi.nlm.nih.gov/pubmed/20961276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2010.0059
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items